Brain Wealthy
    What's Hot

    Leonard Nimoy Once Explained Huge Competitiveness And Anxiety On The Set Of Star Trek

    February 2, 2023

    What Happens During Your Sleep Cycle?

    February 2, 2023

    Humvee details wave of emotions since Ace to Sparks trade

    February 2, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      Leonard Nimoy Once Explained Huge Competitiveness And Anxiety On The Set Of Star Trek

      February 2, 2023

      Therapist Hong Kong News – Counseling and therapy practice treats post-corona depression anxiety and stress Hong Kong

      February 1, 2023

      Pokemon Scarlet & Violet players fail ‘anxiety-inducing’ shiny encounters due to jump glitch

      February 1, 2023

      Can Mindfulness Soothe Anxiety? The trial suggests yes. – Harvard Gazette

      February 1, 2023

      Best CBD for dog anxiety

      February 1, 2023
    • Emotion

      Humvee details wave of emotions since Ace to Sparks trade

      February 2, 2023

      Stephen ‘tWitch’ Boss’ mother shares emotional reaction to seeing his Gap campaign: ‘I almost called you’

      February 1, 2023

      ‘It’s like, really emotional’: Quakertown students Q&A with Super Bowl-bound Eagles player | Southeast Pennsylvania

      February 1, 2023

      Delight in Cafes: Tweets Reveal Where People Express Different Emotions in a City

      February 1, 2023

      Want to be happier?Millions of Tweets Show Your Location May Affect Your Emotions

      February 1, 2023
    • Neurology

      Repairing cerebrospinal fluid leaks may improve symptoms

      February 1, 2023

      Fear of Public Places Associated with Poor Quality of Life in Adults with Epilepsy

      February 1, 2023

      Novartis discontinues Huntington’s disease program after Phase 2b trial

      February 1, 2023

      Postmenopausal stroke risk dates back to women’s reproductive age

      February 1, 2023

      5 Clinical Trial Readouts in Neurology to Look for in 2023

      February 1, 2023
    • Sleep

      What Happens During Your Sleep Cycle?

      February 2, 2023

      Centrepoint will try to sleep out this February.

      February 1, 2023

      Experience America’s Favorite Mattress Tempur-Pedic With The Best Mattress Sleep Specialists – St. George News

      February 1, 2023

      Simple remedies for a good night’s sleep

      February 1, 2023

      Joe Pera launches ‘Drift Off’ podcast to help us fall asleep (again)

      February 1, 2023
    • Brain Research

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023

      Actionable Strategy Report on Brain-Inspired Computing Market

      February 1, 2023

      Disparities associated with differences in brain structure among US children

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Klamath County mental health treatment beds to double in planned expansion

      February 1, 2023

      WIU Introduces Mental Health Awareness Organization to Campus

      February 1, 2023

      Windsor Spitfires Partners with CMHA Windsor-Essex to Host Mental Health Awareness Game

      February 1, 2023

      Mental Health Support – Leeds Parish

      February 1, 2023

      Klamath County mental health treatment beds to double in planned expansion

      February 1, 2023

      WIU Introduces Mental Health Awareness Organization to Campus

      February 1, 2023

      Windsor Spitfires Partners with CMHA Windsor-Essex to Host Mental Health Awareness Game

      February 1, 2023

      Mental Health Support – Leeds Parish

      February 1, 2023
    Brain Wealthy
    Home»Neurology»Neurology Today
    Neurology

    Neurology Today

    brainwealthy_vws1exBy brainwealthy_vws1exDecember 15, 2022No Comments4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Human Epilepsy Project 2 (HEP2) data provide new insights into which antiepileptic drugs (ASMs) are well tolerated and may benefit people with refractory epilepsy, researchers say said at the annual meeting of the American Epilepsy Society in December.

    HEP2, a prospective observational study, was designed to determine whether biomarkers and clinical features can predict disease outcome, progression, and response to treatment in patients with focal epilepsy.

    Researchers recruited 146 patients from 10 epilepsy centers across the United States and followed them from 2016 through 36 months. The participant had focal epilepsy and at least he had failed 4 of her ASMs. The pre-survey mean duration of use included eight different ASMs.

    Investigators collected information on demographics, medical history, seizure history, EEG and MRI results, and past and current ASM medication history. At the start of the study, the patient was taking at least one of her ASMs. Her 45 of the study subjects were diagnosed before her 10th birthday. Her mean age at baseline was 39.7 years.

    “A third of people with epilepsy are prescribed various ASMs for more than 10 years and they do not reduce seizure frequency,” said Jacqueline A. French, MD, FAAN, professor of neurology at the Comprehensive Epilepsy Center. holds a PhD from the NYU Grossman School of Medicine and is Chief Medical/Innovation Officer for the Epilepsy Foundation, which sponsored this study.

    “We want to know what attracts people. [become] Dr. French said: “We want to shorten the journey for these patients to find the right treatment and understand why some drugs work for some and others don’t.”

    The HEP2 data includes information about which drugs participants tried and which they no longer took, and which drugs they were still taking when they entered the study, Dr. French said. .

    In this analysis, among other findings, levetiracetam was the most commonly used ASM overall, with 92.5% reporting lifetime use, followed by lamotrigine at 74% and lacosamide at 67.1%. , carbamazepine at 56.2% and topiramate and zonisamine at 50% each. .

    It is not surprising that levetricetam is the most commonly prescribed ASM over the lifetime of patients, but it is important to confirm that it is one of the drugs with the lowest chance of retention. , said Dr. French.

    After starting ASM, 63.6% of participants continued to use eslicarbazepine. 60%, Brivaracetam. 57.5%, Clobazam. and 38 percent, zonisamide. Phenytoin had the lowest retention rate of 10.8%, while eslicarbazepine and brivaracetam were used less frequently and had higher retention rates. Finally, lacosamide and lamotrigine were relatively commonly used and had high retention rates, suggesting good clinical efficacy and tolerability.

    Dr. France and Texas A&M medical student Ojas Potnis will present their findings at the AES conference and continue to analyze data from the HEP2 study.

    “These patients have been followed for two years to see if anyone is having seizures and why,” Dr. French said.

    Andreas V. Alexopoulos, M.D., M.P.H., Staff Physician and Director of the Neuroscience Course at the Cleveland Clinic Epilepsy Center and Lerner Institute, said: at Lerner College of Medicine.

    “By systematically examining lifetime and current antiepileptic drug use in patients with drug-resistant epilepsy, we are able to catalog patterns of drug use. It may help us understand how we treat patients with drug-resistant focal epilepsy, and may provide lasting benefits.”

    However, Alexopoulos says observational studies have their limitations. “Data quality in similar studies depends on proper documentation of medical records and recall of participants,” he said.

    “It is essential to remember that the results of observational studies cannot be used to prove causality,” added Dr. Alexopoulos. study and extend its conclusions beyond the study cohort to a wider patient population. ”

    Nonetheless, Dr. Alexopoulos said, “Such studies provide a platform that will allow us to identify specific clinical features and potential biomarkers that can be used in the future to predict disease course, outcome, and treatment response.” We can provide it,” he added.

    Dr. French revealed that he received travel coverage from Angelini Pharma SpA, Cerevel, Clinical Education Alliance, NeuCyte Inc., Neurocrine, Praxis, and Xenon.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleAHCA establishes a clearinghouse for providers plagued by audits.President Obama calls for $100 million for brain research
    Next Article Why the Twitter Files released by Elon Musk matter
    brainwealthy_vws1ex
    • Website

    Related Posts

    Repairing cerebrospinal fluid leaks may improve symptoms

    February 1, 2023

    Fear of Public Places Associated with Poor Quality of Life in Adults with Epilepsy

    February 1, 2023

    Novartis discontinues Huntington’s disease program after Phase 2b trial

    February 1, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.